Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
50.45
+5.18 (+11.44%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
15
16
Next >
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
January 27, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
January 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen’s Commitment of $8 Million
January 19, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference
January 03, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
January 03, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023
December 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio
December 12, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend Increase
December 08, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
November 21, 2022
From
Bristol Myers Squibb
Via
Business Wire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
December 08, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
November 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his...
Via
FinancialNewsMedia
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
December 01, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
November 09, 2022
From
Bristol Myers Squibb
Via
Business Wire
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
November 02, 2022
From
Bristol Myers Squibb
Via
Business Wire
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 31, 2022
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Via
TheNewswire.com
Exposures
Product Safety
Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
October 31, 2022
From
Bristol Myers Squibb
Via
Business Wire
MarketBeat: Week in Review 10/24-10/28
October 29, 2022
Stocks finished the week on a bullish note, and the MarketBeat analysts continue to guide you to the stocks and stories that are moving the market
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Economy
Electric Vehicles
Interest Rates
Strong Fundamentals Make Bristol Myers Squibb Stock a Real Value
October 27, 2022
Bristol Myers Squibb stock posts results that establish it as an attractive value stock, even if it may not be as undervalued as it appeared before.
Via
MarketBeat
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
October 26, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
October 25, 2022
From
Bristol Myers Squibb
Via
Business Wire
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program
October 25, 2022
From
Bristol Myers Squibb
Via
Business Wire
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
October 24, 2022
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
October 21, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
October 19, 2022
From
Bristol Myers Squibb
Via
Business Wire
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
October 07, 2022
From
Bristol Myers Squibb
Via
Business Wire
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
October 04, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
September 16, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial
September 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
September 14, 2022
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.